Vapgate-15 Tablet contains tolvaptan 15 mg, a selective vasopressin V2-receptor antagonist that enables controlled aquaresis—removing excess free water while retaining sodium.
It is indicated for the management of hyponatremia associated with conditions such as heart failure, liver cirrhosis and Syndrome of Inappropriate Antidiuretic Hormone (SIADH) as well as slowing progression in adult patients with rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Tolvaptan - 15mg
As directed by the Physician
Hyponatremia Treatment: Vapgate-15 Tablet 4's helps the body eliminate excess water and increase sodium levels in patients with heart failure or SIADH.
ADPKD Treatment: Vapgate-15 Tablet 4's slows the rate of kidney function decline in adults with rapidly progressing ADPKD, potentially delaying disease progression.
Mechanism of Action: By blocking the action of vasopressin at the V2-receptor in the kidney collecting ducts, Vapgate promotes free water excretion without significant loss of electrolytes (sodium and potassium). The result: increased serum sodium concentration, reduction in fluid overload and support in cyst-progression delay in ADPKD.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional and any information contained on or in any product label or packaging and is not intended to diagnose, treat, cure or prevent any disease or disorder. You should consult with a healthcare professional before starting any diet, exercise or nutritional supplement program, before taking any medication, or if you have or suspect you might have a health problem.